Bruno Daniele Selected Research

ARQ 197

1/2018	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
2/2017	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.
11/2016	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
3/2015	Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
4/2014	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.
1/2013	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruno Daniele Research Topics

Disease

39	Hepatocellular Carcinoma (Hepatoma) 03/2022 - 01/2003
34	Neoplasms (Cancer) 04/2022 - 10/2003
12	Disease Progression 01/2022 - 06/2007
11	Colorectal Neoplasms (Colorectal Cancer) 12/2020 - 03/2003
7	Melanoma (Melanoma, Malignant) 01/2022 - 10/2014
7	Liver Neoplasms (Liver Cancer) 09/2021 - 01/2003
6	Breast Neoplasms (Breast Cancer) 04/2022 - 01/2013
4	Fibrosis (Cirrhosis) 10/2020 - 01/2013
4	Prostatic Neoplasms (Prostate Cancer) 12/2018 - 10/2014
4	Neoplasm Metastasis (Metastasis) 11/2017 - 05/2003
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 06/2007
3	Fatigue 07/2021 - 06/2007
3	COVID-19 12/2020 - 01/2020
3	Neutropenia 01/2019 - 01/2013
3	Carcinogenesis 06/2010 - 10/2003
3	Vomiting 06/2007 - 05/2004
2	Triple Negative Breast Neoplasms 04/2022 - 01/2020
2	Ascites 01/2022 - 01/2018
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 01/2019
2	Acute Kidney Injury (Acute Renal Failure) 01/2019 - 01/2018
2	Hepatitis B 01/2016 - 07/2014
2	Adenoma (Adenomas) 02/2013 - 10/2003
2	Pain (Aches) 06/2007 - 01/2006
2	Nausea 01/2007 - 05/2004
1	Rare Diseases (Rare Disease) 04/2022
1	Turcot syndrome 04/2022
1	Microsatellite Instability 04/2022
1	Second Primary Neoplasms (Neoplasms, Second) 07/2021
1	Osteoporotic Fractures 01/2021
1	Hepatitis 10/2020
1	Squamous Cell Carcinoma of Head and Neck 05/2020
1	Emphysema 05/2020
1	Cardiotoxicity 01/2020
1	Diarrhea 01/2020
1	Infections 01/2020
1	Renal Insufficiency (Renal Failure) 01/2019
1	Hepatorenal Syndrome 01/2019
1	Hypertension (High Blood Pressure) 01/2019
1	Liver Diseases (Liver Disease) 01/2019

Drug/Important Bio-Agent (IBA)

23	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 03/2008
9	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2016
7	alpha-Fetoproteins (alpha-Fetoprotein)IBA 09/2021 - 11/2004
6	Immune Checkpoint InhibitorsIBA 04/2022 - 10/2017
6	pembrolizumabIBA 01/2022 - 01/2018
6	ARQ 197IBA 01/2018 - 01/2013
5	RamucirumabIBA 09/2021 - 01/2019
4	Cetuximab (Erbitux)FDA Link 12/2020 - 01/2010
4	Biological ProductsIBA 01/2020 - 05/2006
4	Fluorouracil (Carac)FDA LinkGeneric 01/2013 - 03/2003
3	enzalutamideIBA 03/2022 - 06/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2021 - 05/2006
3	cabozantinibIBA 07/2021 - 01/2020
3	regorafenibIBA 01/2021 - 01/2019
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 05/2006
2	BilirubinIBA 01/2022 - 09/2021
2	PlatinumIBA 07/2021 - 10/2017
2	Cisplatin (Platino)FDA LinkGeneric 07/2021 - 06/2007
2	Lomustine (CCNU)FDA Link 01/2021 - 01/2019
2	Hormones (Hormone)IBA 01/2021 - 03/2008
2	Pharmaceutical PreparationsIBA 12/2020 - 01/2018
2	lenvatinibIBA 01/2020 - 01/2020
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019 - 01/2018
2	Docetaxel (Taxotere)FDA Link 01/2017 - 02/2009
2	Everolimus FDA Link 01/2016 - 07/2014
2	VimentinIBA 02/2013 - 07/2011
2	Epirubicin (Ellence)FDA LinkGeneric 01/2013 - 01/2006
2	Tamoxifen FDA LinkGeneric 03/2008 - 07/2006
2	Leucovorin (Folinic Acid)FDA Link 01/2006 - 03/2003
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2022
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 04/2022
1	Immunoconjugates (Immunoconjugate)IBA 04/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 11/2021
1	AlbuminsIBA 09/2021
1	Transaminases (Aminotransferases)IBA 07/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 03/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2021
1	Bone Density Conservation AgentsIBA 01/2021
1	Vitamin D FDA LinkGeneric 01/2021
1	CalciumIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Panitumumab (Vectibix)FDA Link 12/2020
1	B7-H1 AntigenIBA 10/2020
1	Angiogenesis InhibitorsIBA 05/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	Cell-Free Nucleic AcidsIBA 01/2020
1	Temozolomide (Temodar)FDA LinkGeneric 01/2019
1	Fetal Proteins (Fetoprotein)IBA 01/2019

Therapy/Procedure

26	Therapeutics 04/2022 - 10/2003
17	Drug Therapy (Chemotherapy) 04/2022 - 03/2003
7	Immunotherapy 01/2022 - 10/2014
4	Radiotherapy 05/2020 - 11/2017
3	Castration 12/2018 - 01/2017
3	Surgical Instruments (Clip) 09/2007 - 01/2003
2	Neoadjuvant Therapy 01/2020 - 01/2013
2	Radiofrequency Ablation 04/2004 - 05/2003
1	Continuity of Patient Care 01/2020
1	Chemoradiotherapy 01/2019